Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Jung

Showing results (151-160 of 253) with videos related to

Pageof 26
Sort By:
Archiv Der Pharmazie|November 6, 2023
Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cellsMohamed Abdelsalam, Mariia Zmyslia, Karin Schmidtkunz, et al.
NPJ Aging and Mechanisms of Disease|October 12, 2019
Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagyTugsan Tezil, Manish Chamoli, Che-Ping Ng, et al.
Cancer|January 30, 2019
Avoiding chemotherapy prescribing errors: Analysis and innovative strategiesHeike Reinhardt, Petra Otte, Alison G Eggleton, et al.
Angewandte Chemie (International Ed. in English)|August 3, 2017
Beyond the BET Family: Targeting CBP/p300 with 4-Acyl PyrrolesMartin Hügle, Xavier Lucas, Dmytro Ostrovskyi, et al.
Chembiochem : a European Journal of Chemical Biology|July 17, 2020
HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*Matthias Schiedel, Attila Lehotzky, Sandor Szunyogh, et al.
International Journal of Molecular Sciences|October 27, 2016
Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7Daqiang Pan, Michel Kather, Lucas Willmann, et al.
Chemmedchem|August 10, 2016
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4ALudovica Morera, Martin Roatsch, Michael C D Fürst, et al.
Chemmedchem|March 19, 2011
Carbamate prodrug concept for hydroxamate HDAC inhibitorsSonja Schlimme, Alexander-Thomas Hauser, Vincenzo Carafa, et al.
Frontiers in Oncology|May 20, 2020
Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD<sup>+</sup> Dependent Lysine DeacetylasesNathalie Wössner, Zayan Alhalabi, Jessica González, et al.
European Journal of Medicinal Chemistry|July 19, 2022
Development of hetero-triaryls as a new chemotype for subtype-selective and potent Sirt5 inhibitionCarina Glas, Eli Naydenova, Severin Lechner, et al.
Pageof 26

Showing results (151-160 of 253) with videos related to

Sort By:
Pageof 26
Archiv Der Pharmazie|November 6, 2023
Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cellsMohamed Abdelsalam, Mariia Zmyslia, Karin Schmidtkunz, et al.
NPJ Aging and Mechanisms of Disease|October 12, 2019
Lifespan-increasing drug nordihydroguaiaretic acid inhibits p300 and activates autophagyTugsan Tezil, Manish Chamoli, Che-Ping Ng, et al.
Cancer|January 30, 2019
Avoiding chemotherapy prescribing errors: Analysis and innovative strategiesHeike Reinhardt, Petra Otte, Alison G Eggleton, et al.
Angewandte Chemie (International Ed. in English)|August 3, 2017
Beyond the BET Family: Targeting CBP/p300 with 4-Acyl PyrrolesMartin Hügle, Xavier Lucas, Dmytro Ostrovskyi, et al.
Chembiochem : a European Journal of Chemical Biology|July 17, 2020
HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*Matthias Schiedel, Attila Lehotzky, Sandor Szunyogh, et al.
International Journal of Molecular Sciences|October 27, 2016
Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7Daqiang Pan, Michel Kather, Lucas Willmann, et al.
Chemmedchem|August 10, 2016
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4ALudovica Morera, Martin Roatsch, Michael C D Fürst, et al.
Chemmedchem|March 19, 2011
Carbamate prodrug concept for hydroxamate HDAC inhibitorsSonja Schlimme, Alexander-Thomas Hauser, Vincenzo Carafa, et al.
Frontiers in Oncology|May 20, 2020
Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD<sup>+</sup> Dependent Lysine DeacetylasesNathalie Wössner, Zayan Alhalabi, Jessica González, et al.
European Journal of Medicinal Chemistry|July 19, 2022
Development of hetero-triaryls as a new chemotype for subtype-selective and potent Sirt5 inhibitionCarina Glas, Eli Naydenova, Severin Lechner, et al.
Pageof 26